No abstract available.
Cyclosporine* ; Humans ; Vitiligo*

No abstract available.
Histiocytosis*

No abstract available.
Neurofibromatoses* ; Peripheral Nerves*

We report a case of pityriasis versicolor atrophicans in a 20-year-old woman who presented with chronic multiple brownish atrophic macules and patches on chest and back. The lesions had developed six years ago and the patient had used topical medication including steroid ointments for the last two years prior to visiting our clinic. KOH examination was positive, so skin biopsy was performed and the diagnosis of pityriasis versicolor atrophicans was made. Since our patient had applied topical steroids for some time, it was difficult to rule out steroid-induced atrophy in a common tinea versicolor. Also, differential diagnosis was performed with respect to other skin diseases manifesting with cutaneous atrophy including anetoderma.
Anetoderma ; Atrophy ; Biopsy ; Diagnosis, Differential ; Female ; Humans ; Ointments ; Pityriasis ; Skin ; Skin Diseases ; Steroids ; Thorax ; Tinea Versicolor ; Young Adult

No abstract available.
Exanthema* ; Humans ; Infant* ; Leukemia* ; Leukemia, Myeloid, Acute

No abstract available.
Animals ; Horns* ; Keratoacanthoma*

No abstract available.
Leiomyosarcoma* ; Neoplasm Metastasis* ; Scalp* ; Skin

No abstract available.
Acneiform Eruptions*

BACKGROUND: Atrophic acne scars have been treated using various modalities. The CROSS (Chemical Reconstruction of Skin Scars) technique using 100% TCA has the advantage of reconstructing acne scars by focusing on dermal thickening and collagen production. However, the phenol CROSS technique is not widely used for acne scarring. OBJECTIVE: The purpose of this study was to evaluate the clinical effectiveness and safety of 100% TCA CROSS and phenol CROSS in the treatment of facial atrophic acne scars. METHODS: Twenty-four participants were randomly and equally divided into 2 groups: group 1 received 2 sessions (8 weeks apart) of 100% TCA CROSS, while group 2 received 2 sessions (8 weeks apart) of phenol CROSS. The severity of atrophic acne scarring and treatment efficacies were evaluated by standardized photography, patient satisfaction, physician global assessment, and the ECCA grading scale. Side effects were assessed at the 8- and 20-week visits. RESULTS: At the 0-, 8-, and 20-week visits, both groups showed an acceptable improvement in patient satisfaction and physician global assessment. ECCA grading scale scores improved by a mean of 22.2% (p<0.05) in group 1 and 19.1% (p<0.05) in group 2. The between-group difference in the degree of ECCA score improvement was not statistically significant (p=0.392). Complications such as pain, crust, postcrust erythema, postcrust dryness, and postinflammatory hyperpigmentation were observed in both treatment groups. However, no severe side effects occurred in either group. CONCLUSION: Both 100% TCA CROSS and phenol CROSS are effective treatment modalities for atrophic acne scarring without significant side effects.
Acne Vulgaris* ; Cicatrix* ; Collagen ; Erythema ; Hyperpigmentation ; Patient Satisfaction ; Phenol* ; Photography ; Skin ; Trichloroacetic Acid

No abstract available.
Multiple Myeloma* ; Bortezomib